» Articles » PMID: 31580635

Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins

Overview
Journal ACS Chem Biol
Specialties Biochemistry
Biology
Date 2019 Oct 4
PMID 31580635
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Targeted protein degradation using chimeric small molecules such as proteolysis-targeting chimeras (PROTACs) and specific and nongenetic inhibitors of apoptosis protein [IAP]-dependent protein erasers (SNIPERs) is an emerging modality in drug discovery. Here, we expand the repertoire of E3 ligases capable of ubiquitylating target proteins using this system. By incorporating β-naphthoflavone (β-NF) as a ligand, we developed a novel class of chimeric molecules that recruit the arylhydrocarbon receptor (AhR) E3 ligase complex. β-NF-ATRA, a chimeric degrader directed against cellular retinoic acid binding proteins (CRABPs), induced the AhR-dependent degradation of CRABP-1 and CRABP-2 via the ubiquitin-proteasome pathway. A similar compound ITE-ATRA, in which an alternative AhR ligand was used, also degraded CRABP proteins. Finally, we developed a chimeric compound β-NF-JQ1 that is directed against bromodomain-containing (BRD) proteins using β-NF as an AhR ligand. β-NF-JQ1 induced the interaction of AhR and BRD proteins and displayed effective anticancer activity that correlated with protein knockdown activity. These results demonstrate a novel class of chimeric degrader molecules based on the ability to bring a target protein and an AhR E3 ligase into close proximity.

Citing Articles

Oral SARS-CoV-2 Infection and Risk for Long Covid.

Schwartz J, Capistrano K, Hussein H, Hafedi A, Shukla D, Naqvi A Rev Med Virol. 2025; 35(2):e70029.

PMID: 40074704 PMC: 11903386. DOI: 10.1002/rmv.70029.


Clozapine as an E3 Ligand for PROTAC Technology.

Takano R, Ohoka N, Kurohara T, Arakawa N, Ohgane K, Inoue T ACS Med Chem Lett. 2025; 16(2):258-262.

PMID: 39967646 PMC: 11831399. DOI: 10.1021/acsmedchemlett.4c00500.


Identification of suitable target/E3 ligase pairs for PROTAC development using a rapamycin-induced proximity assay (RiPA).

Adhikari B, Schneider K, Diebold M, Sotriffer C, Wolf E Elife. 2024; 13.

PMID: 39641357 PMC: 11623929. DOI: 10.7554/eLife.98450.


Targeted protein degradation: advances in drug discovery and clinical practice.

Zhong G, Chang X, Xie W, Zhou X Signal Transduct Target Ther. 2024; 9(1):308.

PMID: 39500878 PMC: 11539257. DOI: 10.1038/s41392-024-02004-x.


Principles of paralog-specific targeted protein degradation engaging the C-degron E3 KLHDC2.

Scott D, Dharuman S, Griffith E, Chai S, Ronnebaum J, King M Nat Commun. 2024; 15(1):8829.

PMID: 39396041 PMC: 11470957. DOI: 10.1038/s41467-024-52966-3.